JB Pharma expects India business to grow above market growth rate in FY25: CEO Nikhil Chopra
JB Pharma forecasts its revenues to grow 12-14% and the earnings before interest, tax, depreciation, and amortisation (Ebitda) margins by 27-28% in FY25, the company's top executive said.
Lok Sabha Voting Phase 5: All the latest news
In an interview to ET, Nikhil Chopra, CEO and wholetime director of JB Pharma said he expects the India business to grow above market growth rate led by focus on chronic portfolio, generating more prescriptions, growing top brands, while new order inflows in CDMO business and commercialization of registered products in emerging markets will drive growth in FY25.
«We are very much sure we should be growing (domestic formulation business) around 300 basis points better than the market (growth) in India with the portfolio,» Chopra said.
He added that the growth forecast is based on existing business, and any acquisition will be accretive. Chopra said the contract development and manufacturing organisation (CDMO) business which contributes 13% of total revenue is expected to see growth revving up from second half of FY25 led by new order inflows from Europe, US, and entries into new geographies like Brazil and Mexico. JB Pharma is one of the world's leading producers of lozenges.
«I am projecting the $50-million business to grow to $100 million if all these plans in place now work out. We have capacity, we have partners, we have new products, some of our melatonin (used in treating insomnia) based combinations will start seeing the light probably at the end of this
